在EGFR突变阳性肺癌患者中提供公共援助和生存平等
Kiyoaki Uryu1, Yoshinori Imamura2, Rai Shimoyama3
1Department of Medical Oncology, Yao Tokushukai General Hospital, Yao-shi, Osaka 581-0011, Japan.
Japanese journal of clinical oncology
|December 14, 2024
概括
公共援助和地区城市化对EGFR阳性非小细胞肺癌 (NSCLC) 的日本患者的生存率没有显著影响. 这项真实世界的数据研究发现,基于这些社会经济因素,总体生存率没有显著差异.
科学领域:
- 在瘤学瘤学.
- 公共卫生 公共卫生
- 医疗保健服务研究 医疗服务研究
背景情况:
- 社会经济差异,包括公共援助和住宅城市化,可能会影响癌症治疗结果.
- 表皮生长因子受体 (EGFR) 突变阳性非小细胞肺癌 (NSCLC) 是一个重大的健康问题.
- 了解影响整体生存 (OS) 的因素对于改善患者预后至关重要.
研究的目的:
- 研究公共援助和住宅城市化对EGFR突变阳性NSCLC患者的整体存活 (OS) 的影响.
- 为了分析来自日本NSCLC患者的大量队列的现实世界数据.
- 确定可能影响癌症患者结果的社会经济差异.
主要方法:
- 在日本46家医院 (2010-2020年) 分析了758名用EGFR-氨酸激酶抑制剂治疗NSCLC患者的临床数据.
- 基于公共援助地位和住宅城市化水平 (大都市与其他) 的患者分类.
- 应用单变量和多变量考克斯回归分析来评估OS与各种患者,瘤,治疗和社会经济因素之间的关联.
主要成果:
- 在接受公共援助的患者和没有接受公共援助的患者之间,没有观察到OS的显著差异 (HR 1.084;95% CI,0.674-1.744).
- 同样,在居住在大都市地区和其他地区的患者之间,没有发现OS的显著差异 (HR 1.143;95% CI,0.914-1.428).
- 该研究包括758名患者,其中5.4%接受公共援助,58.3%居住在大都市地区.
结论:
- 公共援助状况不会显著影响日本EGFR突变阳性NSCLC患者的预后.
- 住宅地区的城市化水平也没有与这一患者群体的整体存活率显著相关.
- 这些发现表明,与公共援助和城市化相关的社会经济因素可能不是这一特定NSCLC人群生存的首要决定因素.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
7.9K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.0K
相关概念视频
Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
